Physician profile
Sanjay Kumar Patel
NPI 1043263833
$5,725.85
in general payments reported to CMS, 2019-2025
27 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $336 · 2021: $436 · 2022: $705 · 2023: $372 · 2024: $2,211 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Travel and Lodging: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.35 |
| Travel and Lodging | $1,252.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,379.29 | 2019-2025 | Lensx, Clareon, Rocklatan |
| Ivantis, INC | $323.50 | 2019-2021 | |
| Allergan, INC. | $215.13 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $212.88 | 2020 | |
| Abbvie INC. | $184.79 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.17 | 2019-2020 | |
| Notal Vision, INC. | $168.22 | 2022 | |
| Amgen INC. | $146.36 | 2025 | Tepezza |
| Omeros Corporation | $142.79 | 2019 | |
| Biotissue Holdings INC. | $109.92 | 2021-2022 | |
| Nova Eye, INC. | $86.70 | 2025 | |
| Aerie Pharmaceuticals, INC. | $81.91 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $58.44 | 2021 | |
| Sun Pharmaceutical Industries INC. | $48.46 | 2019-2021 | |
| Depuy Synthes Sales INC. | $45.53 | 2025 | Matrixmidface |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $44.03 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Ocular Therapeutix, INC. | $43.49 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $41.22 | 2024 | Xdemvy |
| Shire North American Group INC | $36.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.28 | 2021-2022 | |
| Glaukos Corporation | $31.11 | 2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Istent Trabecular Micro-Bypass Stent System, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $24.55 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Johnson & Johnson Surgical Vision, INC. | $24.15 | 2022 | |
| Mallinckrodt Enterprises LLC | $23.12 | 2019 | |
| Oyster Point Pharma, INC. | $18.31 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $16.02 | 2023 | Vyzulta |
| Harrow Eye, LLC | $14.21 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.